Global Heparin Market OverviewThe global heparin market is projected to expand at a steady compound annual growth rate of around 5% through 2031, supported by the rising burden of chronic and ...

The mother and daughter received identical diagnoses just over a year apart of multiple myeloma, a blood cancer that occurs ...

Boston Scientific (NYSE:BSX) today announced a definitive agreement to acquire cardiovascular disease treatment device maker ...

Queensland Health staff could have likely prevented the tragic death of a young woman who collapsed while playing cards with ...

The key opportunities in the Blood Clot Retrieval Devices Market involve advancing device technology and improving supply ...

Fragility hip fractures among the elderly are a serious public health concern not for the fracture itself, but from possible ...

When agitated dementia patients wander or shout through the night, families and caregivers understandably feel the need to ...

When is it too late for a patient to file a malpractice claim? It is sometimes unclear when the statute of limitations ...

In a significant move within the medtech industry, Boston Scientific announced on Thursday its intention to acquire Penumbra for approximately $14.5 billion. This acquisition aims to enhance Boston ...

In patients with renal cell carcinoma, a phase 2 trial tested neoadjuvant stereotactic ablative radiation therapy to the inferior vena cava tumor thrombus before radical nephrectomy with thrombectomy.

In a bold move to expand its cardiovascular portfolio, Boston Scientific Corporation has announced its acquisition of Penumbra, Inc. This strategic partnership, valued at approximately $14.5 billion, ...

Boston Scientific’s $374/share Penumbra deal boosts mechanical thrombectomy exposure and growth. Click here to learn more ...